Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists

L-DOPA is the mainstay of treatment for Parkinson’s disease (PD). However, over time this drug can produce dyskinesia. A useful acute PD model for screening novel compounds for anti-parkinsonian and L-DOPA-induced dyskinesia (LID) are dopamine-depleted dopamine-transporter KO (DDD) mice. Treatment w...

Full description

Bibliographic Details
Main Authors:	Vladimir M. Pogorelov, Michael L. Martini, Jian Jin, William C. Wetsel, Marc G. Caron
Format:	Article
Language:	English
Published:	MDPI AG 2023-11-01
Series:	Biomolecules
Subjects:	Parkinson’s disease L-DOPA dyskinesia dopamine dopamine transporter knockout mice dopamine D1 agonists
Online Access:	https://www.mdpi.com/2218-273X/13/11/1658

Similar Items

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
by: Kathryn Lanza, et al.
Published: (2021-03-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01)

Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
by: O. S. Levin, et al.
Published: (2020-12-01)

Alteration of Postural Reactions in Rats with Different Levels of Dopamine Depletion
by: Daria S. Kalinina, et al.
Published: (2023-07-01)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
by: Monica Frazer, et al.
Published: (2023-01-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01)

Irreversible extreme freezing of gait after dopamine agonist withdrawal
by: Mehri Salari, et al.
Published: (2021-08-01)

Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations
by: Manolo eCarta, et al.
Published: (2014-05-01)

Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia
by: Osama F. Elabi, et al.
Published: (2023-07-01)

Proline‐rich transmembrane protein 2 regulates the magnitude and frequency of dopamine release by repetitive neuronal stimuli in the striatum of L‐dopa‐treated mice
by: Daisuke Hatta, et al.
Published: (2024-12-01)

Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease
by: S N Illarioshkin
Published: (2012-06-01)

5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice
by: Demetra Ballardin, et al.
Published: (2024-08-01)

Effects of Dopamine and L-dopa on Ghrelin Gene Expresion in the Hypothalamus and Ovary in a Polycystic Ovarian Syndrome Rat Model
by: Leila Neghaddadgar, et al.
Published: (2024-01-01)

Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease
by: Feras Altwal, et al.
Published: (2021-09-01)

Rats Lacking the Dopamine Transporter Display Inflexibility in Innate and Learned Behavior
by: Anastasia Belskaya, et al.
Published: (2024-06-01)

Predictors of dopamine agonist resistance in prolactinoma patients
by: Elle Vermeulen, et al.
Published: (2020-05-01)

Impulse control disorders and dopamine agonists
by: D. Martins, et al.
Published: (2021-04-01)

Imaging of dopamine in PD and implications for motor and neuropsychiatric manifestations of PD
by: Raul ede la Fuente-Fernandez
Published: (2013-07-01)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
by: Stuart H. Isaacson, et al.
Published: (2023-01-01)

Dopamine Transporter Deficient Rodents: Perspectives and Limitations for Neuroscience
by: Artem Savchenko, et al.
Published: (2023-05-01)

Dopamine-Serotonin Transporter Disease
by: J Gordon Millichap
Published: (2013-04-01)

Dopamine receptors and organ fibrosis
by: ZhongLi Liao, et al.
Published: (2025-03-01)

Dopamine Agonist in Treatment of ADHD with Restless Legs Syndrome and ODD
by: J Gordon Millichap
Published: (2005-05-01)

Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice
by: Yu-Ting Huang, et al.
Published: (2024-04-01)

Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
by: Hiu Fung Wu, et al.
Published: (2024-01-01)

Dopamine transporters : chemistry, biology, and pharmacology /
by: Trudell, Mark L, et al.
Published: (2008)

Dopamine differentially modulates the size of projection neuron ensembles in the intact and dopamine-depleted striatum
by: Marta Maltese, et al.
Published: (2021-05-01)

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
by: Tetsuro Kikuchi, et al.
Published: (2021-06-01)

Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats
by: Maria Ptukha, et al.
Published: (2022-10-01)

The Role of Dopamine in Repurposing Drugs for Oncology
by: Catarina Moura, et al.
Published: (2023-07-01)

Phosphodiesterase 10A (PDE10A): Regulator of Dopamine Agonist-Induced Gene Expression in the Striatum
by: Ryan Bonate, et al.
Published: (2022-07-01)

D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse
by: María Sáez, et al.
Published: (2023-10-01)

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
by: Irena A. Ilovayskaya, et al.
Published: (2023-12-01)

Effect of Grovth Medium on L-Dopa and Dopamine Production Using Citrobacter freundii (NRRL B-2643)
by: Sinan Saydam, et al.
Published: (2022-12-01)

Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease
by: Pierpaolo Turcano, et al.
Published: (2024-05-01)

From Selye’s and Szabo’s Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities
by: Predrag Sikiric, et al.
Published: (2023-12-01)

Dopamine receptor agonists: standard and non-standard applications in medicine
by: E. E. Vasenina, et al.
Published: (2022-03-01)

Role of dopamine in the pathophysiology of Parkinson’s disease
by: Zhi Dong Zhou, et al.
Published: (2023-09-01)

Neurobiology of DOPA as a neurotransmitter /
by: Misu, Yoshimi, 1934-, et al.
Published: (2006)

Progress in the treatment with dopamine receptor agonist-induced impulse control disorders
by: ZHANG Rui, WU Xue-yan
Published: (2022-09-01)